396 related articles for article (PubMed ID: 17128418)
21. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
[TBL] [Abstract][Full Text] [Related]
22. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
23. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
24. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
25. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
27. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
28. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
[TBL] [Abstract][Full Text] [Related]
29. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
30. FLT3 mutations in myeloid sarcoma.
Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
[TBL] [Abstract][Full Text] [Related]
31. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
33. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
34. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.
Li L; Piloto O; Kim KT; Ye Z; Nguyen HB; Yu X; Levis M; Cheng L; Small D
Br J Haematol; 2007 Apr; 137(1):64-75. PubMed ID: 17359372
[TBL] [Abstract][Full Text] [Related]
35. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).
Doubek M; Muzík J; Szotkowski T; Koza V; Cetkovský P; Kozák T; Zák P; Voglová J; Struncová S; Dusek L; Indrák K
Neoplasma; 2007; 54(1):89-94. PubMed ID: 17233551
[TBL] [Abstract][Full Text] [Related]
36. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
[TBL] [Abstract][Full Text] [Related]
37. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
38. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
39. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
[TBL] [Abstract][Full Text] [Related]
40. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]